Why did Dr. Lal PathLabs (LALPATHLAB) stock move recently?

On 7/29/2026, Dr. Lal PathLabs moved +4.3% — The stock extended its post-Q1 rally amid positive analyst commentary, including Kotak Securities naming Dr Lal PathLabs a top pick with a maintained Buy rating and Rs 2,030 fair value. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Dr. Lal PathLabs (LALPATHLAB) overvalued or fairly valued?

MarketChacha shows Dr. Lal PathLabs's valuation in context — a forward P/E of about 43.7, a price-to-book of about 12.6 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Dr. Lal PathLabs's revenue?

Dr. Lal PathLabs reported revenue of ₹2,648 Cr for FY2026, with net profit of ₹508 Cr, per official filings.

What is the share price of Dr. Lal PathLabs (LALPATHLAB)?

Dr. Lal PathLabs last traded at ₹1,877.30 (-2.0% on the day), as of 8/17/2026 — a delayed quote shown for education, not investment advice.

Dr. Lal PathLabs

LALPATHLAB · NSE · Diagnostics · India

Snapshot

TickerLALPATHLAB

ExchangeNSE

SectorDiagnostics

IndustryDiagnostics & Research

CountryIndia

CEOMr. Shankha Banerjee

Employees5,206

HeadquartersGurugram, India

Websitewww.lalpathlabs.com

Filings tracked6

About Dr. Lal PathLabs

Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers phlebotomist training programs. The company was founded in 1949 and is based in Gurugram, India.

Who owns it

Promoters54.8%
Institutions32.2%
Public & other13.1%

109 institutional holders

Ownership breakdown from public market data. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Net margin trend11.8% → 18.3%

Margin has expanded by about 6.4 points — the business is getting more profitable.

Growth qualityrev 8% · PAT 21%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev ₹761 Cr · EPS 8.70

Est. earnings growth +29.3%

Next fiscal year

Rev ₹3,638 Cr · EPS 43.39

Est. earnings growth +16.3%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 5

Revenue (FY2026)

₹2,763 Cr

Net margin

18.3%

Revenue CAGR (3y)

+11.1%

Profit CAGR (3y)

+28.3%

Net profit (FY2026)

₹505 Cr

Ask MarketChacha about LALPATHLAB

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Jul 29, 2026
The stock extended its post-Q1 rally amid positive analyst commentary, including Kotak Securities naming Dr Lal PathLabs a top pick with a maintained Buy rating and Rs 2,030 fair value.
source 1 ↗source 2 ↗· confidence: medium
Jul 27, 2026
Dr. Lal PathLabs shares rose after reporting strong Q1 FY27 results with revenue up 19.1% YoY to ₹798 Cr (highest quarterly growth in 4 years) and PAT up ~28% to ₹169.5 Cr, beating estimates; brokerages including Nomura raised targets on the beat driven by realization gains and volumes.
source 1 ↗source 2 ↗· confidence: high
Jul 24, 2026
Dr. Lal PathLabs rose after reporting Q1 PAT growth of 21% and declaring a ₹5 per share dividend.
source 1 ↗· confidence: high

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2026	₹2,763 Cr	₹505 Cr	18.3%
FY2025	₹2,461 Cr	₹487 Cr	19.8%
FY2024	₹2,227 Cr	₹358 Cr	16.1%
FY2023	₹2,017 Cr	₹239 Cr	11.8%

Quarterly

Period	Revenue	Net profit	Net margin
Q1 FY27	₹798 Cr	₹170 Cr	21.2%
Q4 FY26	₹703 Cr	₹131 Cr	18.7%
Q3 FY26	₹660 Cr	₹91 Cr	13.7%
Q2 FY26	₹731 Cr	₹151 Cr	20.6%
Q1 FY26	₹670 Cr	₹132 Cr	19.8%

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

Filings & announcements

2026

Allotment of ESOP / ESPS
Attached
BSE8/6/2026
Earnings Call Transcript
Attached
BSE7/30/2026
Change in Directorate
Intimation - Tenure Completion of an Independent Director
BSE7/26/2026
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Attached
BSE7/25/2026material
Shareholder Meeting / Postal Ballot-Outcome of AGM
Proceeding of the 32nd AGM is attached
BSE7/25/2026material
Press Release / Media Release
Attached
BSE7/24/2026

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.